Skip to main content
. Author manuscript; available in PMC: 2022 Nov 16.
Published in final edited form as: Circulation. 2021 Sep 30;144(20):1600–1611. doi: 10.1161/CIRCULATIONAHA.121.053521

Figure 5. Comparison of outcome between the study population of FLNCtv carriers (n=85), LMNA mutation carriers (n=46) and DSP mutation carriers (n=60).

Figure 5.

Left panel: all-cause mortality/heart transplantation/left ventricular assist device (D/HT/LVAD) in FLNCtv (green lines) vs LMNA (blue lines) vs DSP carriers (red line). Central panel: Cumulative Incidence Function (CIF) of non-arrhythmic death/HT/LVAD in FLNCtv vs LMNA vs DSP carriers. Right panel: CIF of sudden cardiac death/major ventricular arrhythmias (SCD/MVA) in FLNCtv vs LMNA vs DSP carriers. LMNA patients showed a higher risk of D/HT/LVAD (p=0.017) and non-SCD/HT/LVAD (p=0.006), whereas the risk of SCD/MVA was comparable across the three groups.